

Healthcare Collapse (91)Is the Approval of Meiji HD's "KOSTAIVE" Compensation for Cleaning up the Kaketsuken Scandal?
Masahiro Kami, M.D., Ph.D. President, Medical Governance Research Institute, Tokyo, Japan The COVID-19 vaccine KOSTAIVE, developed by Meiji Seika Pharma, a subsidiary of Meiji Holdings (Meiji HD), is drawing public attention. Social media is overflowing with rumors such as false claims that "shedding from vaccinated individuals can infect others around them." Shedding refers to the idea that after KOSTAIVE proliferates in the recipient’s body, some of it is released into the
Aug 17, 2025


Changing topics, choose and tell―Radiation Classroom
Masaharu Tsubokura, M.D., Ph.D. Chief Professor, Department of Radiation Health Management, School of Medicine, Fukushima Medical...
Aug 3, 2025




















